Synaptogenix (NASDAQ:SNPX) Posts Quarterly Earnings Results, Misses Estimates By $2.30 EPS

Synaptogenix (NASDAQ:SNPX) posted its earnings results on Thursday. The company reported ($4.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.06) by ($2.30), Zacks reports.

Synaptogenix Stock Up 0.4 %

SNPX stock opened at $2.68 on Friday. Synaptogenix has a one year low of $2.15 and a one year high of $6.22. The company has a fifty day moving average price of $2.95 and a two-hundred day moving average price of $3.02.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.